This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NLNK NewLink Genetics (NLNK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About NewLink Genetics Stock (NASDAQ:NLNK) 30 days 90 days 365 days Advanced Chart Get NewLink Genetics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.89▼$14.1052-Week Range N/AVolumeN/AAverage Volume547,540 shsMarket Capitalization$162.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa. Read More Receive NLNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLNK Stock News HeadlinesReproduction DNA and GeneticsAugust 30, 2024 | bbc.co.ukWhat Wall Street expects from NewLink Genetics's earningsJuly 31, 2024 | markets.businessinsider.comBRICS is accumulating all the gold they can get…Five powerful nations are working to unseat the U.S. dollar — and their weapon of choice is gold. Led by the BRICS alliance, this shift is already underway… and it could trigger a historic surge in gold prices. A former gold cycle expert is now revealing what he believes could be the biggest metals move in decades — and how everyday investors can still get positioned in time.July 9 at 2:00 AM | ProsperityPub (Ad)Best DNA Test for 2024May 17, 2024 | cnet.comNewLink Genetics is about to announce earnings — here's what Wall Street expectsMay 14, 2024 | markets.businessinsider.comNewlink Technology Inc.March 20, 2024 | wsj.comHere's what Wall Street expects from NewLink Genetics's earnings reportMarch 6, 2024 | markets.businessinsider.comNewlink Technology Inc (9600)December 19, 2023 | investing.comSee More Headlines NLNK Stock Analysis - Frequently Asked Questions How were NewLink Genetics' earnings last quarter? NewLink Genetics Corp (NASDAQ:NLNK) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, hitting the consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%. What other stocks do shareholders of NewLink Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewLink Genetics investors own include Bristol Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Gilead Sciences (GILD), CSLM Acquisition (SPWR) and Sarepta Therapeutics (SRPT). Company Calendar Last Earnings11/06/2019Today7/09/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:NLNK CIK1126234 Webwww.newlinkgenetics.com Phone515-296-5555FaxN/AEmployees55Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.99 million Net Margins-4,592.84% Pretax MarginN/A Return on Equity-41.50% Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$940 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / BookN/AMiscellaneous Outstanding Shares37,328,000Free FloatN/AMarket Cap$162.00 million OptionableNot Optionable Beta1.17 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:NLNK) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share NewLink Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.